HIGHLIGHTS
- who: Clement Larrue from the (UNIVERSITY) have published the article: Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia, in the Journal: (JOURNAL) of 11/Oct/2022
- how: The authors showed that the small compound OPA1 inhibitor MYLS22 had anti-leukemic activity while sparing normal murine or human hematopoietic cells in_vitro and in_vivo. Patient-derived xenograft assays All animal studies were conducted in accordance with the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care International and with approval of the local ethics committee (Geneva health department authorization GE/123/19 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.